Questcor Pharmaceuticals — Leerink Swann (February 2012)
30 slides from Questcor Pharmaceuticals's conference presentation, Feb 16, 2012
Slide 1: Leerink Swann, February 16, 2012
NASDAQ: QCOR Exhibit 99.1 February 16, 2012 Leerink Swann NASDAQ: QCOR
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Except for the historical information contained herein, this presentation contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to
Slide 3: A biopharmaceutical company whose product, Acthar, helps patients with serious conditions
3 A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions Questcor A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions
Slide 4: Questcor Overview
4 Flagship Product: • Profitable, cash flow positive, $214M** in cash, debt-free • 19 approved indications Key Markets*: • Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms • Several billion dollar market opportunity Strategy: • Continue to grow Acthar sales in each key market • Develop other
Slide 5: Questcor Strategy - Pursue Acthar Markets
5 Questcor Strategy - Pursue Acthar Markets Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Lupus Erythematosus Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Lupus Erythematosus
Slide 6: Acthar and Multiple Sclerosis (MS)
6 Acthar and Multiple Sclerosis (MS) ACTHAR is approved for MS exacerbations, without reference to first line or second line use but is generally positioned as second line as a matter of marketing strategy. See for details. 43% get better or much better 27% get only a little better 30% stay the same
Slide 7: MS Scripts - Record of Consistent Growth
7 Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely rel
Slide 8: Monthly MS Scripts History
8 Monthly MS Scripts History Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the c
Slide 9: Acthar and Nephrotic Syndrome (NS)
9 • Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Acthar is approved “to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic ty
Slide 10: NS Scripts - Strong Q4 Growth
10 Paid Rxs NS Scripts-Strong Q4 Growth Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of
Slide 11: Acthar and Infantile Spasms (IS)
11 • FDA approval 10/15/10 • Devastating, refractory form of childhood epilepsy • IS not responsive to standard anti-epileptic drugs • Unsuccessful treatment may leave infant with permanent developmental disabilities • Considered a medical emergency • Ultra-rare orphan disorder • About half of IS pa
Slide 12: IS Scripts - Higher numbers in H2 2011
12 • Acthar currently used to treat 40-50% of IS patients • Targeting select institutions • Significant variability in quarterly Rxs • Q4-2011 paid Rxs above historic range IS Scripts-Higher numbers in H2 2011 • Acthar currently used to treat 40-50% of IS patients • Targeting select institutions • S
Slide 13: Systemic Lupus Erythematosus (Lupus)
13 • High unmet need; difficult to treat • Serious health risk if unsuccessfully treated • Multiple on-label indications for Acthar – Exacerbations – Maintenance therapy – Lupus nephritis • Large patient population Systemic Lupus Erythematosus (Lupus) • High unmet need; difficult to treat • Serious
Slide 14: Financials
14 Profitable Debt Free Cash Flow Positive Financials Profitable Debt Free Cash Flow Positive
Slide 15: Q3-2011 Financial Results
15 Q3 – 2011 Q3 – 2010 Q3-2011 Financial Results • Third quarter vials shipped: 2,910 • Third quarter cash flow from operations: $32.6M • Channel inventory estimated to be within historic range • Medicaid reserves continue to appear adequate • No shares repurchased Record Net Sales (up 91%) and Soli
Slide 16: Questcor is Cash Flow Positive
16 01/31/12 Questcor is Cash Flow Positive *After return of $78 million of cash to shareholders through share repurchases. Debt-free balance sheet Cash / ST Investments $214M* Accounts Receivable $45M *After return of $78 million of cash to shareholders through share repurchases. Debt-free balance s
Slide 17: Share Repurchases: 15 Million Shares
17 • 2.2 Million Preferred share buyback • 13.2 Common share buyback • $78 million returned to shareholders in stock buybacks • 63.6 million shares currently outstanding • 4.3 million shares remain on buyback authorization Share Repurchases: 15 Million Shares Repurchased shares significantly improve
Slide 18: Preliminary Q4-2011 Metrics
18 • 3,360 Vials Shipped • Net sales of approximately $75 million • Operating expenses expected to be up 20-30% from Q3-2011 • Operating income of approximately $41 million to $43 million • Paid Rxs Q4-11 and January 2012 (estimated) Preliminary Q4-2011 Metrics DX Q4-11 January 2012 Notes: Paid Rx i
Slide 19: How Does Acthar Work?
19 How Does Acthar Work? • Acthar treats autoimmune conditions across a variety of organ systems (CNS, kidney, etc.) • Acthar appears to modulate the immune system and associated inflammatory response through binding to melanocortin receptors • The primary melanocortin peptide (ACTH) in Acthar binds
Slide 20: Biosimilar Pathway Difficult/Impossible
20 • Difficult/impossible to reverse engineer ACTHAR – Not well characterized • Complex pharmacology – Not well characterized • Clinical trial(s) required Biosimilar Pathway Difficult/Impossible • Difficult/impossible to reverse engineer ACTHAR – Not well characterized • Complex pharmacology – Not w
Slide 21: Total $2B+ Acthar Market Opportunity
21 Market Rx Value Market Size Total $2B+ Acthar Market Opportunity MS $40-50K $1B+ NS $150-250K $1B+ IS $100-125K $100M Lupus Unknown Unknown Other Various Unknown
Slide 22: NS Business Already Significant
22 Market Approximate Annualized Net Sales Run Rate* Approximate Annualized Level of Business** NS Business Already Significant MS $145-160M $145-160M NS $60-70M $100-110M IS $40-50M $40-50M Note: Figures do not represent actual net sales ranges for the quarter or year ended December 31, 2011 * Figu
Slide 23: Strategic Plan - Focus on the Embedded Pipeline in Acthar
23 • Expand NS promotion effort • Expand MS promotion effort • Maintain IS promotion effort • Develop pilot rheumatology promotion activity • Develop other markets for Acthar – Acthar is its own pipeline with many other on-label indications and many possible other therapeutic uses – Further define a
Slide 24: Sales Force Expansion - Preliminary Outlook for 2012
24 Sales Force Expansion- Preliminary Outlook for 2012 Q1-12 Q2 Q3 Q4 Q1-13 Possible Rheumatology Possible Rheumatology Sales Pilot Sales Pilot Neuro Hiring & Neuro Hiring & Training Training Neuro Neuro Sizing & Sizing & Alignment Alignment Neph Hiring & Neph Hiring & Training Training Neph Sizing
Slide 25: Investment Highlights
25 Investment Highlights Acthar has sustainable competitive Acthar has sustainable competitive advantages-without FDA approval risk advantages-without FDA approval risk Acthar is approved for 19 indications-many Acthar is approved for 19 indications-many in large markets with sizable unmet need in l
Slide 26: February 16, 2012 Leerink Swann
February 16, 2012 Leerink Swann NASDAQ: QCOR February 16, 2012 Leerink Swann NASDAQ: QCOR
Slide 27: ACTH is a Melanocortin Peptide Derived from POMC
27 ACTH is a Melanocortin Peptide Derived from Pro-opiomelanocortin (POMC) in the Pituitary
Slide 28: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes
28 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC1R Podocytes Renal Mesangial Cells Endothelial Cells (Glomerular, Tubular, Vascular) Tubular Epithelial Cells Macrophages Melanocyt
Slide 29: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes (continued)
29 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC3R CNS Macrophages MC4R Podocytes Renal Mesangial Cells (?) Endothelial Cells (Glomerular, Tubular) Tubular Epithelial Cells CNS MC
Slide 30: MOA of Acthar in NS
30 MOA of Acthar in NS Adapted From Gong 2011 Acthar, Melanocortin Peptides Acthar, Melanocortin Peptides
Questcor Pharmaceuticals — Leerink Swann (February 2012) on 6ix